Does Rallies show 13F holders for CBLL?

Yes. Rallies tracks hedge fund and 13F ownership data for CBLL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CBLL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CBLL. It does not provide personalized investment advice.

CBLL (CeriBell, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

CeriBell, Inc. Common Stock (CBLL) is a publicly traded Healthcare sector company. As of May 20, 2026, CBLL trades at $18.11 with a market cap of $629.09M and a P/E ratio of -12.18. CBLL moved +6.66% today. Year to date, CBLL is -13.02%; over the trailing twelve months it is -0.44%. Its 52-week range spans $10.01 to $32.75. Analyst consensus is strong buy with an average price target of $28.50. Rallies surfaces CBLL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CBLL stock?

Hedge funds tracked by Rallies that own CBLL include Centerbook Partners, Redmile Group, Orbimed Advisors, and Soros Fund. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CeriBell, Inc. Common Stock.

CBLL Key Metrics

Key financial metrics for CBLL
Metric	Value
Price	$18.11
Market Cap	$629.09M
P/E Ratio	-12.18
EPS	$-1.46
Dividend Yield	0.00%
52-Week High	$32.75
52-Week Low	$10.01
Volume	303.61K
Avg Volume	0
Revenue (TTM)	$89.06M
Net Income	$-53.41M
Gross Margin	87.89%

Top Hedge Funds Holding CBLL

Centerbook Partners holds 476.55K shares of CBLL, changed +447.95% as of Sep 30, 2025.
Redmile Group holds 386.79K shares of CBLL, changed -11.13% as of Mar 31, 2026.
Orbimed Advisors holds 112.50K shares of CBLL, changed +0.00% as of Mar 31, 2025.
Soros Fund holds 25.36K shares of CBLL, changed +1.42% as of Mar 31, 2025.

Latest CBLL News

CeriBell Grows Revenue 36% to $89M, Expands EEG Platform into Pediatrics and Delirium — Mar 7, 2026
CeriBell Q4 Sales Jump 34% to $24.8M While Price Target Cut to $28 — Mar 2, 2026
Ceribell’s Q4 Revenue Soars 34% to $24.8M; FDA Clears Neonatal and Delirium Devices — Feb 24, 2026

Recent CBLL Insider Trades

Chao Xingjuan sold 14.00K (~$281.68K) on May 5, 2026.
Chao Xingjuan sold 1.45K (~$29.09K) on May 5, 2026.
Chao Xingjuan sold 23.55K (~$473.20K) on May 5, 2026.

CBLL Analyst Consensus

6 analysts cover CBLL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $28.50.

Common questions about CBLL

Who owns CBLL stock?: Hedge funds tracked by Rallies that own CBLL include Centerbook Partners, Redmile Group, Orbimed Advisors, and Soros Fund. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CeriBell, Inc. Common Stock.
Does Rallies show 13F holders for CBLL?: Yes. Rallies tracks hedge fund and 13F ownership data for CBLL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CBLL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CBLL. It does not provide personalized investment advice.